GlassScriptPhysician profile
Christopher Anyakorah
NPI 1134680069
$3,379.28
in general payments reported to CMS, 2019-2025
18 companies · $1,323 in 2025
The $1,323 reported for 2025 was more than what 90% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $62.72 · 2023: $907 · 2024: $1,087 · 2025: $1,323.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,317.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,316.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,327.07 | 2022-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $405.69 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $392.71 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Pfizer INC. | $298.51 | 2023-2025 | |
| Exact Sciences Corporation | $224.16 | 2023-2025 | Cologuard Collection Kit |
| Abbott Laboratories | $157.16 | 2024-2025 | Freestyle Libre 3 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $113.75 | 2023-2025 | Jardiance, Synjardy, Tradjenta |
| Abbvie INC. | $102.51 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $80.01 | 2023-2025 | Capvaxive, Gardasil 9, Gardasil |
| Glaxosmithkline, LLC. | $51.87 | 2024-2025 | Shingrix, Arexvy |
| Inspire Medical Systems, INC. | $49.28 | 2025 | Inspire |
| Dexcom, INC. | $47.41 | 2025 | Dexcom G6 Transmitter |
| Amgen INC. | $33.51 | 2025 | Repatha |
| Dynavax Technologies Corporation | $23.67 | 2024 | Heplisav-B |
| Hologic Sales and Service, LLC | $19.69 | 2023 | Aptima, Thinprep 2000 Processor |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $19.68 | 2025 | Veozah |
| Shield Therapeutics INC | $19.14 | 2024 | |
| Cranial Technologies, INC | $13.46 | 2023 | Doc Band |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Anyakorah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.